Trial | NCT01657513  Report issue

Title

TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis
Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    60
TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are well-tolerated with few side effects.

Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some do not respond at all while others respond initially but gradually lose effect despite increased dose and more frequent administration.

The cause of treatment failure is largely unknown and it may be production of tnf-alfa neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.
Study Started
Jun 30
2012
Primary Completion
Jul 31
2013
Anticipated
Last Update
Aug 06
2012
Estimate

Drug subjects will receive either infliximab, adalimumab or etanercept

The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug. The study subjects will receive treatment with one drug only - infliximab or adalimumab or etanercept The consulting dermatologist decides which drug to use according to official guidelines

  • Other names: infliximab, adalimumab, etanercept

tnf-alfa treatment (infliximab, adalimumab, or etanercept) Experimental

This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug

Criteria 

Inclusion Criteria:

Male or female
Age above 18
Psoriasis
Indication for treatment with tnf alfa blocking drug
Written informed consent obtained

Exclusion Criteria:

Severe psychiatric disorder
No indication for treatment with tnf-alfa blocking drug
Pregnancy
Breastfeeding
No written informed consent
No Results Posted